STOCK TITAN
  1. Home
  2. News
  3. OPTN

OptiNose Inc - OPTN STOCK NEWS

Welcome to our dedicated news page for OptiNose (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on OptiNose.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OptiNose's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OptiNose's position in the market.

News
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million
Rhea-AI Summary
Optinose announces corporate updates and preliminary first quarter 2024 XHANCE net revenue of $14.9 million. The recent FDA approval for a new indication for chronic rhinosinusitis without nasal polyps in patients 18 years and older is a significant milestone. The Company expects peak XHANCE net revenues to exceed $300 million with incremental spend due to leveraging its current commercial infrastructure. They plan to reach an estimated 3 million patients with chronic sinusitis cared for by ENT and Allergy specialists and potentially expand the market opportunity to over 30 million patients by 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
earnings
-
News
Optinose to Present at the Needham Virtual Healthcare Conference
Rhea-AI Summary
Optinose (NASDAQ:OPTN) will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024. The presentation will be available via webcast on the Optinose website with a replay option for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
conferences
-
News
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Rhea-AI Summary
Optinose (OPTN) receives FDA approval for XHANCE nasal spray to treat chronic rhinosinusitis without nasal polyps, marking a significant breakthrough in treating a debilitating condition affecting millions of adults in the U.S. The drug-device combination product demonstrated a statistically significant reduction in symptoms, sinus inflammation, and acute exacerbations in clinical trials. XHANCE uses a proprietary Exhalation Delivery System to target areas of inflammation deep in the nose. The approval is a crucial advancement in providing effective treatment options for patients suffering from chronic sinusitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
News
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Rhea-AI Summary
Optinose (OPTN) reports fourth quarter and full year 2023 financial results, with XHANCE net revenue of $19.9 million and $71.0 million. The company is awaiting FDA approval for XHANCE for chronic sinusitis treatment by March 16, 2024. Despite revenue decreases, operational efficiency improved, with a net loss of $10.0 million for Q4 2023 and $35.5 million for full year 2023. Cash and cash equivalents stand at $73.7 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
earnings
-
News
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Rhea-AI Summary
Optinose (OPTN) will host a conference call on March 7, 2024, to discuss financial results for the fourth quarter of 2023 and corporate updates. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
earnings
-
News
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Rhea-AI Summary
Optinose (NASDAQ:OPTN) announced the peer-reviewed publication of results from two Phase 3 Clinical Trials evaluating XHANCE for the treatment of chronic sinusitis. The trials showed a significant reduction in symptoms and sinus opacification in patients with chronic rhinosinusitis. XHANCE is a drug-device combination product that uniquely combines a widely used nasal anti-inflammatory drug with an innovative delivery system designed to deliver the medication high and deep into difficult-to-access sinuses and sinonasal drainage tracts. The FDA Supplemental New Drug Application has been filed with a target goal date of March 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
clinical trial
News
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
Rhea-AI Summary
Optinose (OPTN) announced that the FDA has extended the review period for its supplemental new drug application (sNDA) for XHANCE as a treatment for chronic rhinosinusitis, with the updated Prescription Drug User Fee Act (PDUFA) goal date set for March 16, 2024. The FDA requested additional efficacy subset analyses of existing clinical data, leading to the extension. XHANCE could potentially be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis assigned at approximately 10 million patient visits annually.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.33%
Tags
none
-
News
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
Optinose (OPTN) to present company overview and business update at 35th Annual Piper Sandler Healthcare Conference on November 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
News
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
Rhea-AI Summary
Optinose (NASDAQ:OPTN) reports Q3 2023 XHANCE net revenue of $19.8 million, expects net revenue for 2023 to be between $66.0 to $70.0 million. The company's operating efficiency improved as SG&A and R&D expenses decreased by 33%. PDUFA goal date for XHANCE Chronic Rhinosinusitis sNDA is December 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
earnings
News
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
Rhea-AI Summary
Optinose to report Q3 2023 financial results and corporate updates on November 9, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
earnings
Stock OPTN logo
OptiNose Inc

Nasdaq:OPTN

OPTN Rankings

#4300 Ranked by Market Cap
#5025 Ranked by Stock Gains
N/A Ranked by Dividends

OPTN Stock Data

137.44M
82.34M
8.97%
77.6%
2.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Yardley

About OPTN

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo